`
`Celgene Corporation Awarded Additional Patent Protection For Lead
`IMiD(TM), REVIMID(TM);
`Comprehensive Patent Protection for REVIMID Includes Coverage of the
`Active Ingredient, Pharmaceutical Compositions, and Therapeutic Uses
`PR Newswire
`August 28, 2001, Tuesday
`
`Copyright 2001 PR Newswire Association, Inc.
`Section: FINANCIAL NEWS
`Length: 669 words
`Dateline: WARREN, N.J., Aug. 28
`Body
`
`Celgene Corporation (Nasdaq: CELG) announced today that its patent portfolio now includes issued U.S. Patent
`No. 6,281,230 that covers the use of REVIMID(TM), Celgene's lead IMiD(TM) (Immunomodulatory Drug), to treat
`cancer and inflammatory diseases both as a single agent and in combination with other therapies. The patent,
`which issued this morning, also covers all pharmaceutical compositions of REVIMID. Celgene's broad intellectual
`property estate for REVIMID includes U.S. Composition of Matter Patent No. 5,635,517 that covers the active
`ingredient of REVIMID and therapeutic uses of this and other IMiDs. A Re-examination Certificate for this patent,
`issued from the U.S. Patent and Trademark Office over U.S. Patent No. 5,712,291 and other patents, confirms
`Celgene's dominant patent position for its IMiD pipeline. Celgene's comprehensive IMiD patent estate comprises
`several U.S. and foreign patents and numerous additional U.S. and foreign patent applications.
`Below is the chemical structure of REVIMID:
` (Photo: http://www.newscom.com/cgi-bin/prnh/20010828/NYTU033 )
`
` "This patent continues to validate our intellectual property position for the entire IMiD pipeline and its therapeutic
`uses," said Sol J. Barer, Ph.D, President and Chief Operating Officer of Celgene Corporation. "We are committed
`to accelerating our clinical programs for all of the IMiDs and realizing the full potential of this promising pipeline of
`compounds."
`
` Research has demonstrated that IMiDs are novel, small molecule, orally available analogs of thalidomide that are
`designed to be more potent and potentially have a better safety profile than the parent compound. Celgene's IMiDs
`have significantly greater immunological activity than thalidomide in in vitro studies. Data published in The Journal
`of Immunology in 1999 demonstrated that IMiDs potently inhibit the inflammatory cytokines TNF-alpha and
`interleukin (IL)-1 beta while stimulating the anti-inflammatory cytokine IL-10. IMiDs were also reported in the
`November 1, 2000 issue of Blood to enhance T-cell proliferation and IL-2 production.
`
` REVIMID is currently being evaluated as a treatment in multiple myeloma in two Phase I/II clinical trials at the
`Arkansas Cancer Research Center and the Dana-Farber Cancer Institute. Clinical investigators from both
`institutions presented interim data from the trials in May 2001 at the International Myeloma Workshop. REVIMID
`also completed the initial phase of a clinical trial in metastatic melanoma, and based on the results, the trial is being
`expanded to an additional 60 patients who will be treated at greater than 100 mg/day. Further studies are planned
`for REVIMID in anti-inflammatory diseases, in addition to a recently initiated congestive heart failure trial.
`
`
`
`DR. REDDY’S LABS., INC. EX. 1010 PAGE 1
`
`

`

`Page 35 of 115
`Celgene Corporation Awarded Additional Patent Protection For Lead IMiD(TM), REVIMID(TM);Comprehensive
`Patent Protection for REVIMID Includes Coverage of the Act....
`
` Celgene Corporation, headquartered in Warren, New Jersey, is an independent biopharmaceutical company
`engaged in the discovery, development and commercialization of small molecule drugs for the treatment of cancer
`and immunological diseases through gene regulation.
`
` This release contains certain forward-looking statements which involve known and unknown risks, delays,
`uncertainties and other factors not under the Company's control, which may cause actual results, performance or
`achievements of the Company to be materially different from the results, performance or other expectations implied
`by these forward-looking statements. These factors include results of current or pending research and
`development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the
`Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.
` MAKE YOUR OPINION COUNT - Click Here
` http://tbutton.prnewswire.com/prn/11690X82423628
`SOURCE Celgene Corporation
`CONTACT: Robert J. Hugin, Senior Vice President & CFO of Celgene Corporation, +1-732-271-4102
`URL: http://www.prnewswire.com
`Classification
`
`Language: ENGLISH
`
`Subject: PATENTS
`(90%);
`(90%); CHEMICALS PATENTS
`(97%); PHARMACEUTICALS PATENTS
`INTELLECTUAL PROPERTY (90%); CANCER (89%); DISEASES & DISORDERS (89%); MEDICAL RESEARCH
`(89%); ONCOLOGY
`(89%); BIOTECHNOLOGY PATENTS
`(89%);
`INVESTIGATIONS
`(86%); BLOOD
`DISORDERS (77%); DRUG SAFETY (77%); CLINICAL TRIALS (77%); SKIN CANCER (72%); HEART DISEASE
`(72%); CARDIOVASCULAR DISEASE (72%); RESEARCH REPORTS (70%); IMMUNOLOGY (69%); RESEARCH
`INSTITUTES (69%); SCIENCE & TECHNOLOGY (69%); EXECUTIVES (65%)
`
`Company: CELGENE CORP
`(62%); CELGENE
`INC
`INSTITUTE
` DANA-FARBER CANCER
`(97%);
`CORP (97%); DANA-FARBER CANCER INSTITUTE INC (62%); Celgene Corporation PATENT &
`TRADEMARK OFFICE (56%); PATENT & TRADEMARK OFFICE (56%); Celgene Corporation
`
`Organization: PATENT & TRADEMARK OFFICE (56%); PATENT & TRADEMARK OFFICE (56%)
`
`Ticker: CELG (NASDAQ) (97%); CELG (NASDAQ) (97%); CELG
`
`Industry: PHARMACEUTICALS PRODUCT DEVELOPMENT (90%); PHARMACEUTICALS PATENTS (90%);
`CHEMICALS PATENTS
`(90%); BIOTECHNOLOGY
`INDUSTRY
`(89%); ONCOLOGY
`(89%); ANTI-
`INFLAMMATORY AGENTS (89%); BIOTECHNOLOGY PATENTS (89%); IMMUNOLOGIC FACTORS (89%);
`PHARMACEUTICALS INDUSTRY (78%); ACADEMIC MEDICAL CENTERS (78%); INVESTIGATIONAL DRUGS
`(77%); DRUG SAFETY (77%); CLINICAL TRIALS (77%); IMMUNOLOGY (69%); BIOLOGICAL FACTORS (61%)
`
`Person: SOL J BARER (59%)
`
`Geographic: UNITED STATES (79%)
`
`Load-Date: August 29, 2001
`
`
`
`
`End of Document
`
`
`
`
`
`
`
`DR. REDDY’S LABS., INC. EX. 1010 PAGE 2
`
`